Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis

被引：39

作者：

Selvaggio, Anna S. ^{[1
]}

Noble, Paul W. ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA

来源：

ANNUAL REVIEW OF MEDICINE, VOL 67 | 2016年 / 67卷

关键词：

pirfenidone; idiopathic pulmonary fibrosis; interstitial lung disease; Esbriet (R); NECROSIS-FACTOR-ALPHA; OPEN-LABEL; PHASE-3; TRIAL; DOUBLE-BLIND; SURVIVAL; ACETYLCYSTEINE; PROLIFERATION; ACTIVATION; CAPACITY; RECEPTOR;

D O I：

10.1146/annurev-med-120214-013614

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease that has long eluded therapy. Prognosis remains very poor, and currently lung transplantation offers the only hope of survival. Recently, great strides have been made in the development of pharmaceutical therapy to treat IPF. Pirfenidone, an oral antifibrotic agent, has been shown to slow progression of the disease and improve progression-free survival, offering new hope for patients suffering from IPF.

引用

页码：487 / 495

页数：9

共 50 条

[31] Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study
Harari, S.
Caminati, A.
Albera, C.
Vancheri, C.
Poletti, V.
Pesci, A.
Luppi, F.
Saltini, C.
Agostini, C.
Bargagli, E.
Sebastiani, A.
Sanduzzi, A.
Giunta, V.
Della Porta, R.
Bandelli, G. P.
Puglisi, S.
Tomassetti, S.
Biffi, A.
Cerri, S.
Mari, A.
Cinetto, F.
Tirelli, F.
Farinelli, G.
Bocchino, M.
Specchia, C.
Confalonieri, M.
RESPIRATORY MEDICINE, 2015, 109 (07) : 904 - 913
[32] Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis
Jenkins, Gisli
THORAX, 2013, 68 (07) : 603 - 605
[33] Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis
Miyamoto, Atsushi
Morokawa, Nasa
Takahashi, Yui
Ogawa, Kazumasa
Takeyasu, Makiko
Murase, Kyoko
Hanada, Shigeo
Uruga, Hironori
Mochizuki, Sayaka
Takaya, Hisashi
Kurosaki, Atsuko
Kishi, Kazuma
INTERNAL MEDICINE, 2016, 55 (06) : 657 - 661
[34] Pirfenidone In Idiopathic Pulmonary Fibrosis
Carter, Natalie J.
DRUGS, 2011, 71 (13) : 1721 - 1732
[35] Intraindividual Response to Treatment with Pirfenidone in Idiopathic Pulmonary Fibrosis
Loeh, Benjamin
Drakopanagiotakis, Fotios
Bandelli, Gian Piero
von der Beck, Daniel
Tello, Silke
Cordani, Elisa
Rizza, Elvira
Barrocu, Laura
Markart, Philipp
Seeger, Werner
Guenther, Andreas
Albera, Carlo
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (01) : 110 - 113
[36] Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis
Fukihara, Jun
Kondoh, Yasuhiro
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (12) : 1247 - 1254
[37] Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Bonella, Francesco
Wessendorf, Thomas
Costabel, Ulrich
EUROPEAN RESPIRATORY JOURNAL, 2013, 42
[38] Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Kataoka, Kensuke
Taniguchi, Hiroyuki
Kondoh, Yasuhiro
Kimura, Tomoki
Matsuda, Toshiaki
Yokoyama, Toshiki
Yamano, Yasuhiko
Nakahara, Yoshio
Yagi, Mitsuaki
EUROPEAN RESPIRATORY JOURNAL, 2014, 44
[39] Pirfenidone for idiopathic pulmonary fibrosis: could it be a panacea?
Antoniou, Katerina M.
Bouros, Demosthenes
PNEUMON, 2011, 24 (04) : 352 - 354
[40] Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
Chianese, Maria
Screm, Gianluca
Salton, Francesco
Confalonieri, Paola
Trotta, Liliana
Barbieri, Mariangela
Ruggero, Luca
Mari, Marco
Reccardini, Nicolo
Geri, Pietro
Hughes, Michael
Lerda, Selene
Confalonieri, Marco
Mondini, Lucrezia
Ruaro, Barbara
PHARMACEUTICALS, 2024, 17 (06)

← 1 2 3 4 5 →